Abstract
Previously, we showed that long-circulating polyethylene glycol (PEG)-liposomes are cleared rapidly from the circulation when injected repeatedly in the same animal. In this article, we describe the effects of PEG-coating, the circulation time, the lipid dose, and the presence of encapsulated doxorubicin on the pharmacokinetics upon repeated injection in rats. Furthermore, the role of liver and splenic macrophages was investigated. Liposomes without PEG-coating also showed the so-called “enhanced clearance effect”: blood levels at 4 h post injection decreased from 62.8 ± 13.7% of injected dose (%ID) after the first injection to 0.54 ± 0.21%ID after the second injection. This decrease was independent of the circulation time of the first dose. Decreasing the first lipid dose of PEG-liposomes to 0.05 μmol/kg still led to enhanced clearance of a second dose of 5 μmol/kg. No changes in pharmacokinetics were observed when the second dose was 50 μmol/kg. When hepatosplenic macrophages were depleted, no enhanced clearance of repeated liposome injections was observed. A dose of doxorubicin containing PEG-liposomes (Doxil1,2), injected 1 week after injection of empty PEG-liposomes, was cleared rapidly from the circulation in rats. Our results indicate that hepatosplenic macrophages play an essential role in the enhanced clearance effect and that the change in pharmacokinetic behavior upon repeated injection is a general characteristic of liposomes, unrelated to the presence of PEG. Therefore, these findings may have a considerable impact on the clinical application of liposomal formulations that are administered repeatedly.
Footnotes
-
↵1 Doxil is a registered trademark of ALZA Pharmaceuticals, Inc., Mountain View, CA.
-
↵2 Caelyx is a registered trademark of Schering-Plough Pharmaceuticals NV/SA, Brussels, Belgium.
-
The study was supported by Grant NGN 55.3665 from the Technology Foundation (Technologiestichting STW), The Netherlands.
- Abbreviations:
- PEG
- polyethylene glycol
- PHEPC
- partially hydrogenated egg-phosphatidylcholine
- DPPC
- dipalmitoylphosphatidyl-choline
- DSPE
- distearoylphosphatidyl-ethanolamine
- HYNIC
- hydrazinonicotinamide
- %ID
- percentage of injected dose
- p.i.
- post injection
- 99mTc
- technetium-99 m
- PBS
- phosphate-buffered saline
- Received January 18, 2001.
- Accepted April 16, 2001.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|